FDA Plans Proposed Rule To Amend Expedited Safety Reporting Regulations
Executive Summary
FDA is planning to propose additional amendments to its expedited safety reporting regulations based on guidelines issued by the International Conference on Harmonization.
You may also be interested in...
Postmarketing Periodic Reports Should Be Biannual, Not Quarterly - Ligand
Postmarketing periodic adverse event reports should be required every six months following product approval instead of every three months, Ligand suggested in recent comments on FDA's draft guidance "Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines."
Postmarketing Periodic Reports Should Be Biannual, Not Quarterly - Ligand
Postmarketing periodic adverse event reports should be required every six months following product approval instead of every three months, Ligand suggested in recent comments on FDA's draft guidance "Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines."
ICH To Address Postmarketing Issues As Possible Topic At May Meeting
Postmarketing issues surrounding drug products will be taken up as a new topic for consideration at the May meeting of the International Conference on Harmonization Steering Committee in Tokyo.